These important results indicate that mAb 14-25-9-mediated blockade of the immune checkpoint (IC) between PCNA and NKp44 still has the potential to be effective, even in combination with conventional therapy, in promoting NK cells to eliminate a wider portion of the malignant cells including various MM clones. Here, NCR2 is linked to Miyoshi myopathy.